Outcomes of psychotic disorders are associated with high personal, familiar, societal and
clinical burden. There is thus an urgent clinical and societal need for improving those …

Objective: Recent, large, randomized controlled trials (RCTs) showed no benefit of long-
acting injectable (LAI) antipsychotics over oral antipsychotics in preventing relapse in …

Objective: Data on the effectiveness of antipsychotics in the early phase of schizophrenia
are limited. The authors examined the risk of rehospitalization and drug discontinuation in a …

Despite their widespread use, long-acting injectable (LAI) antipsychotics (APs) are often
regarded with some negativity because of the assumption of punishment, control and …

These guidelines from the British Association for Psychopharmacology address the scope
and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving …

These updated guidelines from the British Association for Psychopharmacology replace the
original version published in 2011. They address the scope and targets of pharmacological …

Would you like to include more high interest cases in your Abnormal Psychology course?
Most textbooks on abnormal psychology include short descriptions of actual clinical cases …

Despite treatment advances over the past decades, schizophrenia remains one of the most
severe psychiatric disorders that is associated with a chronic relapsing course and marked …

Schizophrenia is a debilitating chronic disease that requires lifelong medical care and
supervision. Even with treatment, the majority of patients relapse within 5 years, and suicide …

Objective: Nonadherence is a major challenge in schizophrenia treatment. While long-acting
(depot) antipsychotic medications are often recommended to address adherence problems …